The much-anticipated IPO for atai Life Sciences (US:ATAI) ended up being anti-climactic instead.
MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression
MINDCURE announces two, new ketamine-based treatment protocols: one for pain and one for depression. These new protocols will be distributed via iSTRYM.
Novamind Announces US$1,000,000 Strategic Investment in Stealth Mode Drug Development Company
Novamind has just completed a strategic investment of US$1 million in a private psychedelics company, as part of a $25 million Series A financing.
Bright Minds Biosciences Announces Application to List on Nasdaq
Bright Minds Biosciences has applied to uplist to the NASDAQ.
Mydecine Unveils Artificial Intelligence Drug Discovery Program
Mydecine announces a new program to incorporate AI "machine learning" into its drug R&D.
Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004
Cybin's latest R&D initiative (CYB004) is a proprietary molecule targeting anxiety disorders.
Creso Pharma and Red Light Holland Merge to Introduce The HighBrid Lab (TM), a Leading Global Psychedelics x Cannabis Company, Specializing in Recreational Products, Applied Science, Technology and Innovation
Red Light Holland and ASX-listed Creso Pharma are merging to form HighBrid Lab. TRIP CEO Todd Shapiro to lead the combined entity.
It Begins: Bill Introduced Into Congress To Decriminalize All Drugs
A bill to decriminalize drug possession has been introduced into Congress. If passed, jurisdiction for drug classifying would move from the Justice Department to the Department of Health and Human Services.
Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch for FT-104, Its Novel Psychedelic Compound
Field Trip completes another preliminary step toward its Phase I clinical trial of FT-104.
Atai To Upsize IPO Financing To $246 Million, The Industry Leader Just Got Bigger
Atai Life Sciences has re-filed with the SEC to increase its IPO financing from $100 to $246 million. It's a big deal.
Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US
HaluGen Life Sciences' test evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy
MindMed’s New CEO Well-Prepared For Next Stage of Corporate Development
Co-Founder JR Rahn has stepped down as CEO of MindMed. His replacement, Robert Barrow, brings a wealth of clinical trials experience.
